Back to News

Hatch-Waxman 101 for the Emerging Life Science Company

Life Sciences & Healthcare Innovation Program – Previously Recorded


Eastern Time

This program is targeted at innovative life science companies that have filed, or will soon file, NDA or 505(b)(2) applications and are anticipating their first Hatch-Waxman litigation. We will discuss pre-litigation considerations, including Orange Book patent listing, the interplay between patent and regulatory exclusivities, and pre-suit due diligence activities. We will also discuss Hatch-Waxman litigation mechanics, including Notice Letters, 30-month stays of FDA ANDA approval and lawsuit timing.

This webinar is part of our Life Sciences & Healthcare Innovation Program, Cooley’s 14th annual event in conjunction with the J.P. Morgan Healthcare Conference.

View on-demand recording

For more information, please email Jess Karas

Related Contacts
Jonathan Davies  Partner Washington, DC
Sanya Sukduang  Partner Washington, DC